| General Information | |
|---|---|
| ZINC ID | ZINC000028864493 |
| Molecular Weight (Da) | 393 |
| SMILES | CCCCCn1cc(NC(=O)C23CC4CC(CC(C4)C2)C3)c(=O)c2ccccc21 |
| Molecular Formula | C25N2O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 112.605 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| LogP | 5.578 |
| Activity (Ki) in nM | 25.704 |
| Polar Surface Area (PSA) | 51.1 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 1.1339451 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 10 |
| Fraction csp3 | 0.6 |
| Ilogp | 4.38 |
| Xlogp3 | 5.46 |
| Wlogp | 5.16 |
| Mlogp | 3.63 |
| Silicos-it log p | 4.88 |
| Consensus log p | 4.7 |
| Esol log s | -5.51 |
| Esol solubility (mg/ml) | 1.22E-03 |
| Esol solubility (mol/l) | 3.11E-06 |
| Esol class | Moderately |
| Ali log s | -6.29 |
| Ali solubility (mg/ml) | 2.01E-04 |
| Ali solubility (mol/l) | 5.13E-07 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.78 |
| Silicos-it solubility (mg/ml) | 6.47E-05 |
| Silicos-it solubility (mol/l) | 1.65E-07 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.82 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 5.37 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.741 |
| Logd | 4.382 |
| Logp | 5.316 |
| F (20%) | 0.003 |
| F (30%) | 0.008 |
| Mdck | 2.41E-05 |
| Ppb | 0.9047 |
| Vdss | 1.204 |
| Fu | 0.0273 |
| Cyp1a2-inh | 0.142 |
| Cyp1a2-sub | 0.349 |
| Cyp2c19-inh | 0.594 |
| Cyp2c19-sub | 0.284 |
| Cl | 1.916 |
| T12 | 0.034 |
| H-ht | 0.32 |
| Dili | 0.166 |
| Roa | 0.723 |
| Fdamdd | 0.128 |
| Skinsen | 0.028 |
| Ec | 0.003 |
| Ei | 0.012 |
| Respiratory | 0.866 |
| Bcf | 2.547 |
| Igc50 | 4.554 |
| Lc50 | 5.615 |
| Lc50dm | 5.914 |
| Nr-ar | 0.033 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.867 |
| Nr-aromatase | 0.886 |
| Nr-er | 0.287 |
| Nr-er-lbd | 0.013 |
| Nr-ppar-gamma | 0.133 |
| Sr-are | 0.658 |
| Sr-atad5 | 0.003 |
| Sr-hse | 0.851 |
| Sr-mmp | 0.806 |
| Sr-p53 | 0.806 |
| Vol | 421.929 |
| Dense | 0.93 |
| Flex | 25 |
| Nstereo | 0.28 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 4 |
| Toxicophores | 0 |
| Qed | 2 |
| Synth | 0.674 |
| Fsp3 | 3.628 |
| Mce-18 | 0.6 |
| Natural product-likeness | 67.5 |
| Alarm nmr | -0.886 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 4 |
| Gsk | Rejected |
| Goldentriangle | Rejected |